Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.36 |
| ▸ | MME | P08473 | 2/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | PLG | P00747 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | PLAT | P00750 | 1/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6802210 | 0.92 | AKR1C3 (0.42) | KDM4EAKR1C3AKR1C2BDKRB2SIGMAR1 | |
| SCHEMBL6803100 | 0.91 | SIGMAR1 (0.46) | BDKRB2SIGMAR1MMEHDAC3HDAC1 | |
| SCHEMBL6798509 | 0.88 | EPHX1 (0.47) | BDKRB2NPC1RAB9ASMN1; SMN2SIGMAR1 | |
| SCHEMBL6802810 | 0.84 | HTR2A (0.46) | SIGMAR1CYP1A2CYP2A6MMEHDAC3 | |
| SCHEMBL6801926 | 0.82 | SIGMAR1 (0.48) | NPC1RAB9ASMN1; SMN2SIGMAR1ITGB3 | |
| SCHEMBL6800799 | 0.80 | SIGMAR1 (0.49) | SIGMAR1 | |
| SCHEMBL6796754 | 0.78 | HTR2A (0.48) | SIGMAR1CYP1A2CYP2A6MMEACE | |
| SCHEMBL6803279 | 0.76 | SIGMAR1 (0.45) | NPC1RAB9ASMN1; SMN2SIGMAR1 | |
| SCHEMBL8553953 | 0.76 | SIGMAR1 (0.45) | NPC1RAB9ASMN1; SMN2SIGMAR1 | |
| SCHEMBL6803645 | 0.76 | AKR1C3 (0.48) | AKR1C3AKR1C2CYP1A2CYP2A6F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063959-A1 | Esters and amides as PLA2 inhibitors | FUKAMI NAOKI (JP) | 2004-04-01 | — | — | US | disclosed |
| US-20020169326-A1 | Esters and amides as PLA2 inhibitors | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 2002-11-14 | — | — | US | disclosed |
| EP-0854863-B1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-10-30 | — | — | EP | disclosed |
| US-20020019416-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063959-A1 | Esters and amides as PLA2 inhibitors | PLA2G4A, PLA2G2D, PLA2G4B | KDM4E 1993/4885AKR1C3 813/4885AKR1C2 802/4885 |
| US-20020019416-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | PLA2G4A, PLA2G4B, PLA2G1B | KDM4E 1983/4885AKR1C3 795/4885AKR1C2 777/4885 |
| US-20020169326-A1 | Esters and amides as PLA2 inhibitors | PLA2G4A, PLA2G2D, PLA2G4B | KDM4E 2132/4885AKR1C3 733/4885AKR1C2 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.